Skip to main content
Log in

Atomoxetine: profile report

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Simpson D, Perry CM. Atomoxetine. Pediatr Drugs 2003; 5(6): 407–15

    Google Scholar 

  2. Elia J. Atomoxetine: a viewpoint. Pediatr Drugs 2003; 5(6): 416

    Google Scholar 

  3. Safer DJ. Atomoxetine: a viewpoint. Pediatr Drugs 2003; 5(6): 416–7

    Google Scholar 

  4. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996 Apr; 35: 409–32

    Article  PubMed  CAS  Google Scholar 

  5. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63(12): 1140–7

    Article  PubMed  CAS  Google Scholar 

  6. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159(11): 1896–901

    Article  PubMed  Google Scholar 

  7. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108(5):E83–91

    Article  PubMed  CAS  Google Scholar 

  8. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl. 12: 50–5

    PubMed  CAS  Google Scholar 

  9. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002 Jul 1; 67(2): 149–56

    Article  PubMed  CAS  Google Scholar 

  10. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41(7): 776–84

    Article  PubMed  Google Scholar 

  11. Kratochvil C, Wernicke JF, Michelson D, et al. Long-term safety of atomoxetine in the treatment of ADHD [abstract]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2001 Oct 23–28; Honolulu, 119

  12. Atomoxetine (Strattera) for ADHD. Med Lett Drugs Ther 2003 Feb 3; 45 (1149): 11–2

    Google Scholar 

  13. Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 Mar; 109: E39

  14. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, parallel group study of SL1381 (Adderal XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 Mar; 110: 258–66

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elia, J., Safer, D.J. Atomoxetine: profile report. Drugs Ther. Perspect 19, 5–7 (2003). https://doi.org/10.2165/00042310-200319100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319100-00002

Keywords

Navigation